MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from sales andmaturities of investments$19,500K Net cash provided by(used in) investing...$19,500K Net (decrease)increase in cash and cash...$9,083K Canceled cashflow$10,417K Accounts payable$2,390K Stock-based compensationexpense$1,447K Noncash rent expense$546K Other non-currentassets-$44K Depreciation expense$27K Net cash provided by(used in) operating...-$10,232K Net cash provided byfinancing activities-$185K Canceled cashflow$4,454K Net income (loss)-$9,036K Accrued expenses andother current...-$3,587K Proceeds from exercise ofcommon stock options...-$185K Non-current operating leaseliabilities-$980K Prepaid expenses andother current assets$921K (accretion) amortization oninvestments$162K
Cash Flow

Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond Therapeutics, Inc. (BDTX)

source: myfinsight.com